My Cart [ 0 ]
Home > Chemicals > Inhibitors, Activators, Antagonists, and Agonists > A-Z Inhibitors, Activators, Antagonists, and Agonists > PALBOCICLIB (PD-0332991) (HCL SALT)

PALBOCICLIB (PD-0332991) (HCL SALT)

PD-0332991

Catalog No. Product Name Size List Price (US$) Quantity
APIM050217 PALBOCICLIB (PD-0332991) (HCL SALT) 50mg 85.00
APIM050217 PALBOCICLIB (PD-0332991) (HCL SALT) 100 mg 120.00
APIM050217 PALBOCICLIB (PD-0332991) (HCL SALT) 200 mg 190.00
APIM050217 PALBOCICLIB (PD-0332991) (HCL SALT) 500 mg 350.00
Description

Background Information:

Palbociclib (PD-0332991) is an orally bioavailable, potent and highly selective cyclindependent kinase 4 and 6 (CDK 4/6) with IC50 at 11 and 16 nM, respectively.

Reference:

1. Rivadeneira, Dayana B.; Mayhew, Christopher N.; Thangavel, Chellappagounder; Sotillo, Elena; Reed, Christopher A.; Grana, Xavier; Knudsen, Erik S. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology (2010), 138(5), 1920-1930.
2. Dean, J. L.; Thangavel, C.; McClendon, A. K.; Reed, C. A.; Knudsen, E. S. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene No pp. yet given. CODEN: ONCNES ISSN:0950-9232. AN 2010:612647.
3. Michaud, Karine; Solomon, David A.; Oermann, Eric; Kim, Jung-Sik; Zhong, Wei-Zhu; Prados, Michael D.; Ozawa, Tomoko; James, C. David; Waldman, Todd. Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts. Cancer Research (2010), 70(8), 3228-3238.

APIM050217: PALBOCICLIB (PD-0332991) (HCL SALT)

CAS No.: 827022-32-2
Molecular Formula: C24H29N7O2 ? HCl.
Molecular Weight: 484.0 (or refer to Certificate of Analysis).
Purity: >99.5% (HPLC at 214 and 254 nm).
QC: HPLC, 1HNMR.
Solubility: Soluble in DMSO and water.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.

Related Links

See our Privacy Policy